Pfizer: CDK4/6 new drug palbociclib First in class, will break $5 billion this year Recently, Pfizer released its Q3 financial report for 2019 and disclosed its results for the first three quarters.Pfizer Q3's global performance was 12.68 billion US dollars; the first three quarters of the performance was 39.062 billion US dollars.
Pfizer Biopharmaceuticals Group (PBG) - Pfizer Biopharmaceuticals (including innovative drugs, biosimilars, hospitals focused on anti-infectives and sterile injectables), with a performance of $28.887 billion in the first three quarters of 2019.The mature
Pharmaceutical business unit (composed of patent expired brand drugs and generic drugs) is Upjohn, with a performance of $8.077 billion in the first three quarters of 2019.
The consumer health sector's results for the first three quarters of 2019 were $2.098 billion.
Pfizer's global product performance in the first three quarters of 2019
Ibrance, the world's first CDK4/6 inhibitor, has a global revenue of $3.677 billion.27% year-on-year growth;The product is expected to exceed the $5 billion mark in FY 2019. It was first approved in the United States in February 2015. After more than four years, it became a super blockbuster.
The world's first cyclin-dependent kinase (CDK) 4/6 inhibitor, IBRANCE® ( palbociclib) was approved by the Chinese National Drug Administration (NMPA) on July 31, 2018. IBRANCE® for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer, should be combined with aromatase inhibitors as postmenopausal women Initial endocrine therapy.
Peirnar 13 vaccine (Prevnar 13) first quarter results of 4.268 billion US dollars
Xeljanz (Tofacitinib) had a previous quarterly performance of $1.634 billion. (There are already two generic drugs approved for listing in China, Qilu Pharmaceuticals Tofacitinib, listed in advance!)
The first three quarters of Eliquis (Apixaban) were $3.121 billion. (including cooperation with BMS performance and direct sales performance) (Rivaroxaban broke 1.2 billion domestically, a lot of generic drugs for Apixaban to sell!)Other products of pregabalin, atorvastatin, enzalutamide, sunitinib, crizotinib, infliximab, axitinib, sildenafil (Viagra), TNFR-Fc fusion protein The first three quarters were 2.88 billion, 1.506 billion, 594 million, 704 million, 385 million, 446 million, 316 million, 379 million, 1.285 billion.
Pfizer China Pfizer's performance in 2019Q3 was 2.195 billion US dollars, down 26% year-on-year. It was mainly affected by the patent cliff of the US market Pregabalin, and the impact of generic drugs started in July 2019.Pfizer's China's third-quarter results only increased by 2%(Vain, which is not included in the volume purchase, sildenafil citrate continues to climb).Pfizer is expected to be in China,Pu Qiang`s performance is compared with 2018,In financial year 2019, there will be an increase in the median to high number (5% to 9%).
Pfizer China as a whole grew 42% in 2019 Q3,The main growth comes from the Pfizer China Biopharmaceuticals segment. Growth is driven by products such as palbociclib, tofacitinib, and apixaban.
The mid-year report shows that Pfizer`s China`s second quarter results in 2019 fell 20%.The decline was affected by the purchase of 4+7 drugs, and the old products such as Lipitor (Atorvastatin) and Luohuxi (Amlodipine);During the same period, Pfizer China Biopharmaceuticals increased by 26%. Pfizer Strong China's first quarter results in 2019 increased by 13%.
